BioCentury | Jun 30, 2020
Product Development

Second death in Audentes gene therapy trial may highlight need for more careful dosing

The report of a second patient death in a trial of an AAV8-based gene therapy from Audentes and Astellas renewed decades-old concerns over the modality’s safety, but the adverse events may reflect a need for...
BioCentury | May 2, 2019
Clinical News

Modest differences in outcomes for doses of Audentes myopathy gene therapy

Audentes presented updated data from the Phase I/II ASPIRO trial of AT132 to treat X-linked myotubular myopathy (XLMTM) showing that the trial's low and high doses had comparable safety and efficacy profiles. Chairman and CEO...
BioCentury | Oct 12, 2018
Financial News

Gene therapy company Audentes raises $151M

On the heels of data for one of its gene therapies, Audentes Therapeutics Inc. (NASDAQ:BOLD) raised $150.8 million on Oct. 10 through the sale of 5.2 million shares at $29 in a follow-on underwritten by...
BioCentury | Aug 10, 2018
Clinical News

Audentes reports Phase I/II muscle biopsy data for myopathy gene therapy

Audentes Therapeutics Inc. (NASDAQ:BOLD) reported data from its 24-week muscle biopsy analyses of the first dose cohort and said an IDMC recommended proceeding to the second dose cohort of the Phase I/II ASPIRO trial evaluating...
BioCentury | May 25, 2018
Clinical News

Audentes reports updated Phase I/II myopathy data for AT132

Audentes Therapeutics Inc. (NASDAQ:BOLD) reported updated interim data from the first cohort of the open-label, dose-escalation, U.S. Phase I/II ASPIRO trial testing AT132 in patients with X-linked myotubular myopathy (XLMTM). The presentation at the American...
BioCentury | May 18, 2018
Clinical News

Audentes rises on additional myopathy data

Audentes Therapeutics Inc. (NASDAQ:BOLD) ended the week at $38.24, up $4.04 (12%), after an oral presentation of updated interim data from the first cohort of the dose-escalation Phase I/II ASPIRO trial testing AT132 in patients...
BioCentury | Jan 5, 2018
Clinical News

Audentes reports interim Phase I/II data for XLMTM candidate

Gene therapy company Audentes Therapeutics Inc. (NASDAQ:BOLD) reported interim data from the first cohort of the Phase I/II ASPIRO trial of AT132 to treat X-linked myotubular myopathy, a rare monogenic disease characterized by extreme muscle...
BioCentury | Nov 18, 2016
Financial News

AmpliPhi completes follow-on

AmpliPhi raised $4 million through the sale of 5.3 million shares at $0.74 and 5.3 million five-year warrants at $0.01 per warrant in a follow-on underwritten by Roth Capital Partners and Griffin Securities. Each warrant...
BioCentury | Oct 31, 2016
Financial News

Xtant Medical amends rights offering

ItemBodyText Xtant Medical Holdings Inc. (NYSE-M:XTNT), Belgrade, Mont. Business: Supply/Service, Musculoskeletal Date announced: 2016-10-21 Type: Rights offering To be raised: Up to $15 million Shares: 15 million Price: $1 (unit) Shares outstanding prior: 12.2 million...
BioCentury | Oct 10, 2016
Financial News

Provectus Biopharmaceuticals proposes rights offering

Provectus Biopharmaceuticals Inc. (NYSE-M:PVCT), Knoxville, Tenn. Business: Cancer, Autoimmune, Dermatology Date announced: 2016-10-05 Type: Rights offering To be raised: TBD Shares: TBD Price prior: $0.09 Shares outstanding prior: 212.8 million Investor: Existing investors Underwriter: Maxim...
Items per page:
1 - 10 of 77